BioSystem Development announces the release of AssayMAP MAb Titer Assay

BioSystem Development, LLC., a privately held life science analytics company, announces the release of the AssayMAP MAb Titer Assay for measuring antibody product concentrations (or titers) in bioprocess samples.

Antibody titer assays are a critical bottleneck in biotherapeutic process development. Although the current “gold standard” method – protein A affinity HPLC – is reliable, selective, sensitive and precise, its throughput is severely limited to merely 4 – 12 samples an hour. The AssayMAP MAb Titer assay uses exactly the same chemistry as Protein A HPLC with a 100-fold increase in throughput, equivalent analytical performance and no need for specialized instrumentation. AssayMAP cartridges, filled with POROS® MabCapture™ A media from Life Technologies Corporation, offer rapid, small-scale parallel analysis either manually in a spin-column format or on common automation platforms and measure IgG concentration across a wide dynamic range ideally suited for process development without a need for sample dilution.

“This launch is a significant milestone in the evolution of the AssayMAP platform,” said Scott Fulton, founder and CEO. “It is the first assay we adapted to a spin-column format that requires only common lab equipment to perform, making AssayMAP solutions readily available for researchers when investment in new instrumentation platforms is not possible.”